Systematic review of 47 studies (30 RCTs) in older adults with AML unfit for intensive chemotherapy: azacitidine or LDAC plus venetoclax probably reduces mortality and improves remission and quality of life; decitabine combinations gave inconsistent effects.
Meta-analysisn = 47 studies
Oliveros et al. Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis